US FDA accepts NDA for Insys’ fentanyl cancer breakthrough pain drug
This article was originally published in Scrip
Executive Summary
The US FDA accepted for review the new drug application (NDA) for Insys Therapeutics’ fentanyl sublingual spray as a treatment for breakthrough pain in cancer patients.